×

Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)

SAN FRANCISCO and GENEVA, Sept. 12, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that it has completed enrollment of the originally planned 72 patient LP-002 clinical study to assess the commercial feasibility of the company's flagship Alzheimer's blood diagnostic LymPro Test®. Amarantus previously released positive interim data from LP-002 on July 31, 2014 and expects to release data on the predictive value of individual LymPro markers (univariate) from the full cohort of 72 patients in the coming weeks.

"We look forward to releasing additional univariate data from the originally-planned 72 patient LP-002 clinical study in the near-term," said Gerald E. Commissiong, President & CEO of Amarantus. "We believe this data set will further position Amarantus to successfully target our initial Research Use Only (RUO) customer with LymPro as a stage-independent diagnostic, as discussed in our recent business update call."

Mr. Commissiong will be making a presentation today at the Aegis Capital 2014 Healthcare and Technology Conference that will be web cast live at 10:00 AM PT and available at http://wsw.com/webcast/aegis/ambs/.

The LP-002 trial was designed to replicate previously published peer-reviewed findings that demonstrated that LymPro was able to correctly distinguish Alzheimer's disease patients from healthy controls. LP-002 is evaluating LymPro's accuracy in both severe and moderate Alzheimer's disease. The subjects in the trial were recruited from four centers across the United States in order to mimic commercial shipping logistics for Laboratory Developed Tests ("LDT") under Clinical Laboratory Improvement Amendments ("CLIA"). Becton Dickinson's facility in La Jolla, CA is serving as the laboratory for LP-002. Amarantus is currently validating LymPro at Icon Central Laboratories ahead of commercial launch as an LDT.

About LymPro Test®

The Lymphocyte Proliferation Test (LymPro Test ®) is a diagnostic blood test that measures the ability of peripheral blood lymphocytes to withstand an external mitogenic stimulation that induces them to enter the cell cycle. It is hypothesized that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons. LymPro is unique in the use of peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain. LymPro is currently enrolling LP-002, clinical trial to evaluate the feasibility of LymPro to correctly diagnose Alzheimer's disease. LymPro is being developed as a diagnostic blood test for Alzheimer's disease and is being evaluated as a test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.

About Amarantus Bioscience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for orphan ophthalmological disorders and other indications. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located in offices and labs at Janssen Labs @QB3. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

CONTACT: Amarantus Bioscience Holdings, Inc. Aimee Boutcher, Investor Relations 408.737.2734 x 101 ir@amarantus.com Planet Communications Deanne Eagle, Media Contact (917) 837-5866

Source:Amarantus BioScience Holdings, Inc.